Plan-based 1,230-share sale by Enliven (ELVN) director disclosed

Rhea-AI Filing Summary

Enliven Therapeutics director Richard A. Heyman reported an open-market sale of 1,230 shares of common stock at a weighted average price of $26.1759 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024 for an associated trust account.

After this transaction, the filing shows 22,647 shares remaining in the indirectly held account that sold the shares, additional indirect holdings of 25,545 shares, and 123,673 shares held directly. Certain indirect holdings are through the Heyman Daigle Trust and RAHD Capital LLC, entities for which he serves as trustee or managing member.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		1,230	D	$26.1759(2)	22,647	I	See footnote(3)
Common Stock								123,673	D
Common Stock								25,545	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

2. This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held of record by the Heyman Daigle Trust.

4. The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.

	/s/ Ben Hohl, by power of attorney	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enliven Therapeutics (ELVN) disclose?

Enliven Therapeutics disclosed an insider open-market sale of 1,230 common shares linked to director Richard A. Heyman. The shares were sold at a weighted average price of $26.1759 per share under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024.

Who was involved in the latest Enliven Therapeutics (ELVN) Form 4 filing?

The Form 4 lists director Richard A. Heyman as the reporting person. The sale occurred in an account held indirectly, with related entities including the Heyman Daigle Trust and RAHD Capital LLC, where he serves as trustee or managing member according to the filing footnotes.

How many Enliven Therapeutics (ELVN) shares were sold and at what price?

The filing reports a sale of 1,230 common shares at a weighted average price of $26.1759 per share. A footnote explains the trade executed in multiple lots at prices ranging from $25.765 to $26.6949, with the average price disclosed.

Was the Enliven Therapeutics (ELVN) insider sale under a 10b5-1 plan?

Yes. The reported sale was effected under a Rule 10b5-1 trading plan adopted on November 15, 2024. Such plans allow pre-scheduled trades, helping insiders diversify holdings while following regulatory guidelines on trading while potentially possessing material nonpublic information.

How many Enliven Therapeutics (ELVN) shares does the insider hold after this sale?

After the sale, the filing shows 123,673 shares of Enliven Therapeutics common stock held directly. It also reports 22,647 shares remaining in the indirectly held selling account and another indirect holding of 25,545 shares, reflecting multiple ownership accounts.

What do the Enliven Therapeutics (ELVN) Form 4 footnotes reveal about ownership?

Footnotes state that some shares are held of record by the Heyman Daigle Trust and by RAHD Capital LLC. Richard A. Heyman serves as trustee or managing member of these entities, which hold the reported indirect positions in Enliven Therapeutics common stock.